Woodmont Investment Counsel LLC Acquires 12,883 Shares of Pfizer Inc. (NYSE:PFE)

Woodmont Investment Counsel LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 120,054 shares of the biopharmaceutical company’s stock after purchasing an additional 12,883 shares during the period. Woodmont Investment Counsel LLC’s holdings in Pfizer were worth $3,332,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. VisionPoint Advisory Group LLC grew its holdings in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the last quarter. GoalVest Advisory LLC grew its holdings in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Creekmur Asset Management LLC purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC increased its stake in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the period. Finally, Tennessee Valley Asset Management Partners purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $36,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, June 26th. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Morgan Stanley upped their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Nine investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $35.54.

Pfizer Price Performance

Shares of PFE stock traded down $0.39 on Tuesday, reaching $27.83. The company’s stock had a trading volume of 12,856,852 shares, compared to its average volume of 40,569,621. The stock’s fifty day simple moving average is $27.90 and its 200-day simple moving average is $27.69. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $37.80. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $157.70 billion, a price-to-earnings ratio of -466.59, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. Pfizer’s revenue was down 19.5% on a year-over-year basis. During the same period last year, the company earned $1.23 earnings per share. Analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a $0.42 dividend. The ex-dividend date is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a yield of 6.04%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.